Pharvaris (NASDAQ:PHVS) Insider Anna Nijdam Sells 5,501 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 5,501 shares of the company’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $30.74, for a total value of $169,100.74. Following the completion of the sale, the insider owned 48,945 shares of the company’s stock, valued at approximately $1,504,569.30. This trade represents a 10.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The shares were sold at an average price of $30.60, for a total value of $55,967.40.

Pharvaris Stock Up 0.7%

Shares of Pharvaris stock opened at $29.88 on Wednesday. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -9.40 and a beta of -2.34. The business has a fifty day simple moving average of $28.61 and a 200-day simple moving average of $26.96. Pharvaris N.V. has a fifty-two week low of $15.46 and a fifty-two week high of $33.33.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. Analysts anticipate that Pharvaris N.V. will post -3.25 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PHVS has been the subject of several analyst reports. Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Citizens Jmp reduced their target price on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Wedbush upped their target price on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Finally, Wolfe Research initiated coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price for the company. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.18.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Stempoint Capital LP raised its position in Pharvaris by 48.4% during the first quarter. Stempoint Capital LP now owns 86,637 shares of the company’s stock valued at $2,447,000 after buying an additional 28,248 shares during the period. ADAR1 Capital Management LLC raised its position in Pharvaris by 23.4% during the first quarter. ADAR1 Capital Management LLC now owns 105,528 shares of the company’s stock valued at $2,981,000 after buying an additional 20,000 shares during the period. Amundi raised its position in Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock valued at $874,000 after buying an additional 3,312 shares during the period. Rock Springs Capital Management LP raised its position in Pharvaris by 3.6% during the first quarter. Rock Springs Capital Management LP now owns 645,533 shares of the company’s stock valued at $18,236,000 after buying an additional 22,131 shares during the period. Finally, SummitTX Capital L.P. raised its position in Pharvaris by 27.7% during the first quarter. SummitTX Capital L.P. now owns 29,184 shares of the company’s stock valued at $824,000 after buying an additional 6,325 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.